Compare Shopify Inc. (SHOP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shopify Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Shopify Inc. trades at $169.84 (market cap $227.12B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Shopify Inc. is far larger — about 46.5× Travere Therapeutics Inc. Common Stock's market cap, and Shopify Inc. is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Shopify Inc. for 78 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SHOP | TVTX | |
|---|---|---|
Market Cap | $227.12B | $4.88B |
Volume | 6,965,160 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $179.22 | $67.52 |
52-Week Low | $95.40 | $26.79 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $222.35B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHOP trades at $172.50, down 3.75% today but maintains a bullish technical outlook with strong moving average support. The company shows robust revenue growth from $5.6B in 2022 to $11.6B in 2025, though valuation ratios remain elevated with a P/E of 119.27. Recent news highlights Shopify's AI innovations including Canvas site-building tool and open AI agent checkout, positioning it favorably against competitors.
Shopify's outlook remains positive with 67% analyst buy ratings and $172.47 consensus target. Key opportunities include AI-driven commerce expansion and merchant solutions growth accelerating to 37%. Risks include high valuation multiples and competitive pressure from Amazon's opposing AI strategy. The stock offers growth potential but requires monitoring of earnings sustainability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
